683 Capital Management LLC Purchases 197,338 Shares of Lexeo Therapeutics, Inc. $LXEO

683 Capital Management LLC lifted its position in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) by 21.4% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 1,120,000 shares of the company’s stock after acquiring an additional 197,338 shares during the quarter. 683 Capital Management LLC’s holdings in Lexeo Therapeutics were worth $11,122,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Avoro Capital Advisors LLC bought a new position in shares of Lexeo Therapeutics during the 4th quarter worth $32,769,000. Spruce Street Capital LP purchased a new stake in shares of Lexeo Therapeutics during the 4th quarter worth $1,738,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Lexeo Therapeutics during the 4th quarter worth $190,000. AQR Capital Management LLC lifted its stake in shares of Lexeo Therapeutics by 370.0% during the 1st quarter. AQR Capital Management LLC now owns 50,337 shares of the company’s stock worth $175,000 after purchasing an additional 39,627 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey lifted its stake in shares of Lexeo Therapeutics by 171.1% during the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 16,373 shares of the company’s stock worth $163,000 after purchasing an additional 10,333 shares during the last quarter. Institutional investors own 60.67% of the company’s stock.

Insider Activity at Lexeo Therapeutics

In related news, CEO Richard Nolan Townsend sold 55,000 shares of the company’s stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $5.69, for a total value of $312,950.00. Following the sale, the chief executive officer owned 340,106 shares in the company, valued at $1,935,203.14. This represents a 13.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 59,644 shares of company stock worth $336,462 over the last three months. Insiders own 2.00% of the company’s stock.

Lexeo Therapeutics Stock Performance

Lexeo Therapeutics stock opened at $4.98 on Thursday. The stock has a 50-day moving average of $5.46 and a two-hundred day moving average of $6.95. Lexeo Therapeutics, Inc. has a one year low of $3.60 and a one year high of $10.99. The stock has a market cap of $391.03 million, a PE ratio of -3.43 and a beta of 1.38.

Lexeo Therapeutics (NASDAQ:LXEO) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. As a group, sell-side analysts predict that Lexeo Therapeutics, Inc. will post -1.23 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Weiss Ratings upgraded Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, June 11th. Wall Street Zen upgraded Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, Chardan Capital reiterated a “buy” rating and issued a $17.00 price target on shares of Lexeo Therapeutics in a research note on Monday, May 11th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $20.14.

Lexeo Therapeutics Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.